egeneron's Lynozyfic Gains EC Conditional Approval for Relapsed Multiple Myeloma
CompanyDrug

Regeneron’s Lynozyfic Gains EC Conditional Approval for Relapsed Multiple Myeloma

NMPA Issues New Quality Management Standards for Online Medical Device Sales
Policy / Regulatory

NMPA Issues New Quality Management Standards for Online Medical Device Sales

BeiGene's Sonrotoclax NDA Accepted by NMPA for CLL/SLL Treatment
CompanyDrug

BeiGene’s Sonrotoclax NDA Accepted by NMPA for CLL/SLL Treatment

NHSA Launches Intelligent Supervision Reform Pilot in Designated Medical Institutions
Policy / Regulatory

NHSA Launches Intelligent Supervision Reform Pilot in Designated Medical Institutions

Shanghai Pharmaceuticals Posts Modest Q1 Revenue Growth, Sees Profit Decline
Company

Shanghai Pharmaceuticals Posts Modest Q1 Revenue Growth, Sees Profit Decline

OUR United Corporation Files for IPO in Hong Kong Stock Exchange
CompanyDeals

OUR United Corporation Files for IPO in Hong Kong Stock Exchange

Henlius Biotech's HLX22 Receives Clinical Trial Approval in Germany for HER2-Positive Cancers
CompanyDrug

Henlius Biotech’s HLX22 Receives Clinical Trial Approval in Germany for HER2-Positive Cancers

GenScript to Acquire Additional Stake in Probio Cayman for USD 225.1 Million
CompanyDeals

GenScript to Acquire Additional Stake in Probio Cayman for USD 225.1 Million

CSPC Pharmaceutical Reports 7.8% Revenue Decline in 2024 Amid VBP Impact
Company

CSPC Pharmaceutical Reports 7.8% Revenue Decline in 2024 Amid VBP Impact

Innovent Biologics Posts 51.8% YOY Revenue Growth in 2024 Financial Report
Company

Innovent Biologics Posts 51.8% YOY Revenue Growth in 2024 Financial Report

Hengrui Pharmaceuticals Gains NMPA Clinical Clearance for Camrelizumab in Acral Melanoma
CompanyDrug

Hengrui Pharmaceuticals Gains NMPA Clinical Clearance for Camrelizumab in Acral Melanoma

Shouyao Holdings Gets Ethics Approval for SY-5933 Phase Ib/II Study in KRAS G12C Mutated Tumors
CompanyDrug

Shouyao Holdings Gets Ethics Approval for SY-5933 Phase Ib/II Study in KRAS G12C Mutated Tumors